C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market

ST. LOUIS--(BUSINESS WIRE)-- #Alzheimers--C₂N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today announced a partnership agreement with Mediford Corporation, a PHC Holdings Corporation (TSE 6523) Group Company and premier provider of clinical research to the biopharma industry throughout Japan. The agreement greatly increases access to C₂N Biopharma Clinical Research Services, which offers highly sensitive mass spectrometry-based identification